Completed trials
Explore a selection of our completed trials, along with how to access data and publications.
DolPHIN-1
Safety and pharmacokinetics of dolutegravir in pregnant HIV mothers and their neonates: a pilot study.
This study randomised treatment naïve pregnant women with HIV (28-36 weeks gestation) in Uganda and South Africa to dolutegravir or efavirenz (1:1) as part of their antiretroviral treatment. The study found that despite low plasma dolutegravir exposures in the third trimester, transfer across the placenta and through breastfeeding was observed, with persistence in infants likely due to slower metabolic clearance. HIV RNA suppression <50 copies/mL was twice as fast with DTG compared to EFV, suggesting dolutegravir has potential to reduce risk of vertical transmission in mothers who are initiated on treatment late in pregnancy.
Publications
- Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)
doi:10.1371/journal.pmed.1002895 - Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1
doi:10.1093/cid/ciaa1861
DolACT
Dolutegravir interactions with artemisinin-based combination therapies.
This study looked at drug-drug interactions between the most common artemisinin containing therapies used for malaria treatment, artemether-lumefantrine or artesunate-amodiaquine, and the HIV medication, dolutegravir. The study found that standard doses of the antimalarial drugs should be used with dolutegravir.
The trial is registered on clinicaltrials.gov NCT02242799.
Publications